Breaking News

Cingulate, Societal CDMO Enter Mfg. Pact for ADHD Drug

Societal CDMO will manufacture all clinical, registration, and commercial batches of Cingulate’s lead candidate CTx-1301.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cingulate Inc., a biopharmaceutical company utilizing its Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, has executed a Master Services Agreement (MSA) with Societal CDMO, Inc., a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development.   With capabilities spanning pre-Investig...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters